Dennis McCarty1, Brian Chan, Bradley M Buchheit, Christina Bougatsos, Sara Grusing, Roger Chou. 1. From the Department of Medical Informatics and Clinical Epidemiology, Pacific Northwest Evidence-Based Practice Center, Oregon Health & Science University, BICC, Portland, OR (DM, CB, SG, RC), Department of Medicine, OHSU Medical School, Oregon Health & Science University, Portland, OR (DM, BC, BMB), Department of Family Medicine, School of Medicine, Oregon Health & Science University, Portland, OR (BMB).
Abstract
OBJECTIVE: A scoping review assessed access to medications for opioid use disorder (MOUD) and treatment outcomes among adolescents (12 - 17 years) and young adults (18 - 25 years). METHODS: Studies addressing adolescent and young adult opioid use disorder and treatment with MOUD on patient outcomes (eg, retention in care) were included. Randomized trials and controlled observational studies were prioritized. Investigators extracted key information, summarized findings, noted methodological weaknesses, and tabled the details. RESULTS: The search identified 4 randomized trials (N = 241), 1 systematic review with 52 studies (total N = 125,994), and 5 retrospective analyses of health insurance claims. The trials reported buprenorphine and extended-release naltrexone reduced opioid use. Return to use was observed when pharmacotherapy ceased. A systematic review concluded that adolescents and young adults had lower retention in care than older adults. The observational studies found that adolescents were unlikely to receive MOUD. There was some evidence that non-Hispanic Black adolescents and young adults were less likely than non-Hispanic Whites to receive MOUD. CONCLUSIONS: MOUD therapies reduce opioid use among adolescent and young adults but few receive MOUD. MOUD services for adolescents and young adults should be developed and tested. Randomized clinical trials are necessary to develop appropriate clinical guidelines for using MOUD with adolescents and young adults.
OBJECTIVE: A scoping review assessed access to medications for opioid use disorder (MOUD) and treatment outcomes among adolescents (12 - 17 years) and young adults (18 - 25 years). METHODS: Studies addressing adolescent and young adult opioid use disorder and treatment with MOUD on patient outcomes (eg, retention in care) were included. Randomized trials and controlled observational studies were prioritized. Investigators extracted key information, summarized findings, noted methodological weaknesses, and tabled the details. RESULTS: The search identified 4 randomized trials (N = 241), 1 systematic review with 52 studies (total N = 125,994), and 5 retrospective analyses of health insurance claims. The trials reported buprenorphine and extended-release naltrexone reduced opioid use. Return to use was observed when pharmacotherapy ceased. A systematic review concluded that adolescents and young adults had lower retention in care than older adults. The observational studies found that adolescents were unlikely to receive MOUD. There was some evidence that non-Hispanic Black adolescents and young adults were less likely than non-Hispanic Whites to receive MOUD. CONCLUSIONS: MOUD therapies reduce opioid use among adolescent and young adults but few receive MOUD. MOUD services for adolescents and young adults should be developed and tested. Randomized clinical trials are necessary to develop appropriate clinical guidelines for using MOUD with adolescents and young adults.
Authors: Laura J Chavez; Andrea E Bonny; Katharine A Bradley; Gwen T Lapham; Jennifer Cooper; William Miller; Deena J Chisolm Journal: J Adolesc Health Date: 2020-04-08 Impact factor: 5.012
Authors: Rachel H Alinsky; Scott E Hadland; Pamela A Matson; Magdalena Cerda; Brendan Saloner Journal: J Adolesc Health Date: 2020-04-24 Impact factor: 5.012
Authors: Scott E Hadland; Sarah M Bagley; Jonathan Rodean; Michael Silverstein; Sharon Levy; Marc R Larochelle; Jeffrey H Samet; Bonnie T Zima Journal: JAMA Pediatr Date: 2018-11-01 Impact factor: 16.193
Authors: Carrie M Mintz; Ned J Presnall; John M Sahrmann; Jacob T Borodovsky; Paul E A Glaser; Laura J Bierut; Richard A Grucza Journal: Drug Alcohol Depend Date: 2020-06-18 Impact factor: 4.492
Authors: Fatema Z Ahmed; Barbara Andraka-Christou; M H Clark; Rachel Totaram; Danielle N Atkins; Brandon Del Pozo Journal: Health Justice Date: 2022-07-27